Literature DB >> 9000149

Allelotyping of all chromosomal arms in invasive cervical cancer.

J S Rader1, T Kamarasova, P C Huettner, L Li, Y Li, D S Gerhard.   

Abstract

The best characterized factor in the development of cervical cancer is the integration, of human papillomavirus into cervical cell chromosomes. In addition to HPV integration, the neoplastic process probably requires the activation of cellular protooncogenes and loss of tumor suppressor gene function. Loss of heterozygosity analysis in a large sample is used to identify regions which harbor putative tumor suppressor genes (TSG) since the deletion of normal alleles unmask mutated alleles. We evaluated tumor tissue from invasive cervical carcinomas, carefully microdissected to eliminate normal stroma and lymphocytes, for LOH at all 41 chromosomal arms with 50 polymorphic markers. We have evaluated tumor and normal DNA pairs from 48 invasive cervical cancers of which 85% of the tumors are confined to the cervix. The mean loss for all chromosomal arms was 12%. Three regions exhibited LOH two standard deviations above the mean: 3p14.1-12 (40%), 11q23.3 (36%), and 6p22-21.3 (32%). Three regions showed loss one standard deviation above the mean: 19q13.4 (30%), 6q21-23.33 (25%), and 2q33-37 (24%). Our results indicate that a significant number of invasive cervical cancers have lost specific chromsomal regions, thereby suggesting that genes involved in the cell cycle regulation or the suppression of tumor development are located in these regions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9000149

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  Patterns of allelic loss (LOH) in vulvar squamous carcinomas and adjacent noninvasive epithelia.

Authors:  M C Lin; G L Mutter; P Trivijisilp; K A Boynton; D Sun; C P Crum
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

2.  Allelic loss in human papillomavirus-positive and -negative vulvar squamous cell carcinomas.

Authors:  A P Pinto; M C Lin; G L Mutter; D Sun; L L Villa; C P Crum
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

3.  Nab1, a corepressor of NGFI-A (Egr-1), contains an active transcriptional repression domain.

Authors:  A H Swirnoff; E D Apel; J Svaren; B R Sevetson; D B Zimonjic; N C Popescu; J Milbrandt
Journal:  Mol Cell Biol       Date:  1998-01       Impact factor: 4.272

Review 4.  Fragility Extraordinaire: Unsolved Mysteries of Chromosome Fragile Sites.

Authors:  Wenyi Feng; Arijita Chakraborty
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

5.  Molecular biology of squamous cell carcinoma of the anus: a comparison of HIV-positive and HIV-negative patients.

Authors:  Pascal Gervaz; Dieter Hahnloser; Bruce G Wolff; Sarah A Anderson; Julie Cunningham; Robert W Beart; Adam Klipfel; Lawrence Burgart; Stephen N Thibodeau
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

Review 6.  Molecular events in uterine cervical cancer.

Authors:  S A Southern; C S Herrington
Journal:  Sex Transm Infect       Date:  1998-04       Impact factor: 3.519

7.  Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix.

Authors:  A M Kersemaekers; J Hermans; G J Fleuren; M J van de Vijver
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

8.  Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer.

Authors:  L A Koopman; W E Corver; A R van der Slik; M J Giphart; G J Fleuren
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

9.  Genetic variation and its role in malignancy.

Authors:  Bente A Talseth-Palmer; Rodney J Scott
Journal:  Int J Biomed Sci       Date:  2011-09

10.  Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions.

Authors:  Hugo Arias-Pulido; Gopeshwar Narayan; Hernan Vargas; Mahesh Mansukhani; Vundavalli V V S Murty
Journal:  Mol Cancer       Date:  2002-10-01       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.